175 related articles for article (PubMed ID: 24152053)
1. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.
Åsberg A; Bjerre A; Neely M
Pediatr Transplant; 2014 Feb; 18(1):103-11. PubMed ID: 24152053
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.
Villeneuve D; Brothers A; Harvey E; Kemna M; Law Y; Nemeth T; Gantt S
Pediatr Transplant; 2013 Feb; 17(1):80-5. PubMed ID: 23240598
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N; Csajka C; Pascual M; Manuel O; Lamoth F; Meylan P; Aubert JD; Venetz JP; Soccal P; Decosterd LA; Biollaz J; Buclin T
Antimicrob Agents Chemother; 2009 Jul; 53(7):3017-23. PubMed ID: 19307355
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.
Vaudry W; Ettenger R; Jara P; Varela-Fascinetto G; Bouw MR; Ives J; Walker R;
Am J Transplant; 2009 Mar; 9(3):636-43. PubMed ID: 19260840
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
9. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
Tängdén T; Cojutti PG; Roberts JA; Pea F
Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment Failure.
Jorga K; Reigner B; Chavanne C; Alvaro G; Frey N
CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):167-176. PubMed ID: 30354026
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning.
Ponthier L; Autmizguine J; Franck B; Åsberg A; Ovetchkine P; Destere A; Marquet P; Labriffe M; Woillard JB
Clin Pharmacokinet; 2024 Apr; 63(4):539-550. PubMed ID: 38492206
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O; Pascual M; Perrottet N; Lamoth F; Venetz JP; Decosterd LA; Buclin T; Meylan PR
Clin Transplant; 2010; 24(6):794-800. PubMed ID: 20105200
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
Padullés A; Colom H; Bestard O; Melilli E; Sabé N; Rigo R; Niubó J; Torras J; Lladó L; Manito N; Caldés A; Cruzado JM; Grinyó JM; Lloberas N
Antimicrob Agents Chemother; 2016 Apr; 60(4):1992-2002. PubMed ID: 26824942
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
Wong DD; van Zuylen WJ; Craig ME; Rawlinson WD
Rev Med Virol; 2019 Mar; 29(2):e2023. PubMed ID: 30556615
[TBL] [Abstract][Full Text] [Related]
15. Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir.
Trevillyan J; Angus P; Shelton E; Whitlam J; Ierino F; Pavlovic J; Gregory D; Urbancic K; Torresi J; Testro A; Grayson ML
Antimicrob Agents Chemother; 2013 Aug; 57(8):4058-60. PubMed ID: 23733466
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients.
Franck B; Woillard JB; Théorêt Y; Bittencourt H; Demers E; Briand A; Marquet P; Lapeyraque AL; Ovetchkine P; Autmizguine J
Br J Clin Pharmacol; 2021 Aug; 87(8):3105-3114. PubMed ID: 33373493
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.
Vezina HE; Brundage RC; Balfour HH
Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients 4 Months of Age and Younger.
Bradley D; Moreira S; Subramoney V; Chin C; Ives J; Wang K;
Pediatr Infect Dis J; 2016 Dec; 35(12):1324-1328. PubMed ID: 27580058
[TBL] [Abstract][Full Text] [Related]
20. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
